

Session Time	Presentation Time	Session Type	Session Title	Presentation Title	Room	UChicago Participant	Poster Board
Friday, June 2							
1:00 PM	1:15 PM	Education Session	Molecular Profiling in Neuro-oncology: Where Are We, Where Are We Headed, and How Do We Ensure Everyone Can Come Along?	Precision Oncology Trials for Primary Brain Tumors: One Size Does Not Fit All	S102	Mei-Yin Polley, PhD	
1:00 PM	1:12 PM	Oral Abstract Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft	Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.	S100bc	Gregory Roloff, MD	
2:00 PM - 2:45 PM	2:00 PM - 2:45 PM	Education Session	Personalizing Surveillance in Head and Neck Cancer	Monitoring and Surveillance in Head and Neck Cancer	S102	Chair: Nishant Agrawal, MD	
2:45 PM - 5:45 PM	2:45 PM - 5:45 PM	Oral Abstract Session	Central Nervous System Tumors	Central Nervous System Tumors	S100a	Chair: Steven Chmura, MD, PhD	
2:45 PM - 4:15 PM	2:45 PM - 4:15 PM	Clinical Science Symposium	Gynecologic Cancer	Knives Out: Surgical Management of Gynecologic Cancers	E451	Chair: John Moroney, MD	
1:00 PM - 4:00 PM	2:36 PM	Oral Abstract Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft	Myeloid for Measure: New Therapeutics in Myelodysplastic Syndromes and Acute Myeloid Leukemia	S100a	Discussant: Anand Ashwin Patel, MD	
Saturday, June 3							
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Developmental Therapeutics—Immunotherapy	Comparing the impact of steroid sparing immunosuppression vs. steroid monotherapy for immune-related adverse events in non-small cell lung cancer and melanoma.	Hall A	Sharjeel Syed, MD	479
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Developmental Therapeutics—Immunotherapy	Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.	Hall A	Mark Charles Korpics, MD, MS	435
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Genitourinary Cancer—Prostate, Testicular, and Penile	Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.	Hall A	Kunal Desai, MD, MS, MBA	156
1:15 PM	1:15 PM	Ticketed Session	Genitourinary Cancer—Kidney and Bladder	Meet the Professors: Horses, Zebras, and Unicorns—Variant Histologies in Urothelial Cancer	E253d	Piyush K. Agarwal, MD	
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Central Nervous System Tumors	The clinical relevance of margins in frameless stereotactic radiosurgery for intact brain metastases: A randomized trial of 0 vs 2 mm margins.	Hall A	Aditya Juloori, MD	437a
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Health Services Research and Quality Improvement	Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction (PCR) versus next-generation sequencing (NGS) testing strategies in metastatic non-small cell lung cancer (mNSCLC).	Hall A	Christine M. Bestvina, MD	130
1:15 PM	N/A	Oral Abstract Session	Hematologic Malignancies—Plasma Cell Dyscrasia	Combinations Still in the Spotlight	Hall D2	Discussant: Andrzej J. Jakubowski, MD, PhD	
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Prevention, Risk Reduction, and Hereditary Cancer	Prevalence of and racial/ethnic distribution of full-body skin examination among sexual and gender minority patients.	Hall A	Jincong Q. Freeman, MS, MPH	190
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Health Services Research and Quality Improvement	Understanding patient acceptance and compliance of a blood-based colorectal cancer screening test.	Hall A	Karen Kim, MD	145b
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Health Services Research and Quality Improvement	Incidence of infusion related reactions of daratumumab-hyaluronidase-fhij: Pre-post intervention study of premedication omission.	Hall A	Kashyap Padmaraju, PharmD	66
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Melanoma/Skin Cancers	A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.	Hall A	Daniel Olson, MD	362b
3:00 PM - 4:30 PM	N/A	Poster Discussion Session	Developmental Therapeutics—Immunotherapy	A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.	S100bc	Matthew Koshy, MD	
3:00 PM - 4:30 PM	3:00 PM	Poster Discussion Session	Developmental Therapeutics—Immunotherapy	Exits Off the Auto Heme Malignancy Track for CAR T	S100bc	Michael R. Bishop, MD	
3:00 PM - 4:30 PM	N/A	Poster Discussion Session	Developmental Therapeutics—Immunotherapy	Developmental Therapeutics—Immunotherapy	S100bc	Chair: Randy Sweis, MD	
3:00 PM - 6:00 PM	4:36 PM	Oral Abstract Session	Gynecologic Cancer	Mining the Landscape of Immunotherapy in Uterine Cancer	Hall D1	Discussant: Gini F. Fleming, MD	
3:00 PM - 6:00 PM	N/A	Oral Abstract Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	Association of somatic mutations and histologic subtype/grade on prognosis and PD-L1 expression in mesothelioma.	Hall B1	Allen Zhu, PhD	
Sunday, June 4							
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Breast Cancer—Local/Regional/Adjuvant	Treatment outcomes in patients with discordant recurrence score and RSClin risk predictions.	Hall A	Augustin Vannier	49
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	Dares: A phase II trial of durvalumab and ablative radiation in extensive stage small cell lung cancer.	Hall A	Aditya Juloori, MD	90
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Breast Cancer—Metastatic	Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.	Hall A	Nan Chen, MD, MS	316
8:00 AM	8:00 AM	Education Session	Pediatric Oncology	Putting It Together: Big Data in Pediatric Oncology	S406	Chair: Samuel Louis Volchenboum, MD, PhD	
8:00 AM	8:30 AM	Education Session	Artificial Intelligence for Drug Development: Fad or Future?	Pathology Image-Based Detection of Clinically Actionable Genetic Alterations	S100b	Chair: Alexander T. Pearson, MD, PhD	
9:45 AM - 12:45 PM	N/A	Oral Abstract Session	Pediatric Oncology I	Pediatric Oncology I	S100a	Chair: Ami Desai, MD, MSCE	
9:45 AM - 12:45 PM	10:09 AM	Oral Abstract Session	Pediatric Oncology I	A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHN study.	S100a	Tara O. Henderson, MD, FASCO, MPH	
11:30 AM - 1:00 PM	11:30 AM - 1:00 PM	Poster Discussion Session	Breast Cancer—Metastatic	HER2-Low: Learning As We Go	Hall D2	Discussant: Rita Nanda, MD	
11:30 AM - 12:45 PM	11:30 AM - 12:45 PM	Education Session	Hematologic Malignancies: The Times, They Are a Changing: Updates to Pathologic and Prognostic Classifications in Myeloid Malignancies	Understanding the 2022 WHO and ICC Classifications of Myeloid Neoplasms	S406	Chair: Sandeep Gurbuxani, MD, PhD	
Monday, June 5							
7:30 AM - 9:30 AM	7:30 AM - 9:30 AM	Education Session	Professional Development and Education Advances	Oncology Division Chiefs and Department Chairs' Breakfast	N229	Chair: Sonali M. Smith, MD, FASCO	
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary	Multi-institutional study evaluating the role of circulating tumor DNA (ctDNA) in management of appendiceal cancers (AC).	Hall A	Erika Belmont, MD	491
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Oral Abstract Session	Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology	Breaking Bad Barriers: Brain-Penetrant Small Molecule Inhibitors	Hall D2	Ardaman Shergill, MD	
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Oral Abstract Session	Pediatric Oncology II	Pediatric Oncology II	S504	Chair: Mark Applebaum, MD	
8:00 AM	8:00 AM	Oral Abstract Session	Head and Neck Cancer	Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.	Hall B1	Ari Rosenberg, MD	
8:00 AM	8:00 AM	Education Session	Treatment Decisions for Resectable Non-Small Cell Lung Cancer: Balancing Less With More	Resection of Localized Lung Cancer	E450	Chair: Jessica Donington, MD	
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft	Effect of disease status prior to T-cell depleted allogeneic stem cell transplantation on relapse-free and overall survival in patients with adverse-risk acute myeloid leukemia (AML).	Hall A	Alexandra Ewa Rojek, MD	179
8:00 AM - 11:00 AM	8:00 AM - 11:00 AM	Poster Session	Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft	A phase I study of MEK inhibitor selumetinib in combination with azacitidine in patients with higher-risk chronic myeloid neoplasia.	Hall A	Gregory Roloff, MD	208b
9:45 AM - 11:15 AM	9:45 AM - 11:15 AM	Clinical Science Symposium	Special Session	Moving Cellular Therapy Into Earlier Lines of Treatment in Hematologic Malignancies: Latest Efficacy Data and The Need to Improve Access	Hall D1	Chair: Kunle Odunsi, MD, PhD	
11:30 AM - 1:00 PM	11:30 AM - 1:00 PM	Poster Discussion Session	Hematologic Malignancies	Leukemia, Myelodysplastic Syndromes, and Allograft	E450	Chair: Michael Drazer, MD	
11:30 AM	11:30 AM	Case-Based Panel	Professional Development and Education Advances	Addressing Grief, Burnout, and Well-Being in the Practice of Oncology	S102	Chair: Fay J. Hlubocky, PhD, MA	
1:00 PM - 2:15 PM	1:00 PM	Education Session	Lung Cancer: Family Matters: Germline Testing in Thoracic Cancers	Basics of Germline Testing and Approaches to Genetic Counseling	E451	Feighanne Hathaway, MSc	
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Symptoms and Survivorship	The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).	Hall A	Sweetha Nakshatri, BS	66
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Care Delivery and Regulatory Policy	Evolving adjuvant estrogen therapy prescribing among breast oncology workforce.	Hall A	Kayla Polcari, MD, MPH	140
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Gynecologic Cancer	RT-PACE: Phase VII study of adjuvant whole pelvic hypofractionated radiotherapy for non-metastatic cervical and endometrial cancer.	Hall A	Christina H. Son, MD	316b
1:15 PM - 4:15 PM	1:15 PM - 4:15 PM	Poster Session	Head and Neck Cancer	Randomized phase VII trial of TheraT vectors expressing HPV16 specific antigens with neoadjuvant chemotherapy followed by transoral robotic surgery (TORS) or risk/response stratified chemoradiotherapy (CRT) for locoregional HPV16+ oropharyngeal cancer (OPC)	Hall A	Ari Rosenberg, MD	100a
3:00 PM	N/A	Oral Abstract Session	Prevention, Risk Reduction, and Hereditary Cancer	Polygenic risk score calibration and association with breast cancer in diverse ancestries.	S100a	Olufunmilayo I. Olopade, MBBS, FASCO, FACP	
4:30 PM	N/A	Poster Discussion Session	Pediatric Oncology	Identifying osteosarcoma signatures in cell free DNA using 5-hydroxymethylcytosine profiling.	S504	Evan W Neczypor, BS	
4:30 PM	N/A	Poster Discussion Session	Pediatric Oncology	Intensity at the end of life in pediatric neuro-oncology patients: The case for pediatric palliative care.	S504	Chinwe Udemgba	